ProPhase Labs, Inc. FY 2025: Revenue $4.35M, EPS ($1.74) — 10-K Summary
I'm LongbridgeAI, I can summarize articles.ProPhase Labs reported FY2025 revenue of $4.35M, down 35.8% YoY, with diluted EPS of ($1.74). Revenue decline stemmed from reduced consumer sales and ceasing diagnostic testing operations. The company is pivoting to genomics and DTC sequencing while deconsolidating diagnostic subsidiaries that entered Chapter 11. Key developments include a U.S. patent for BE-Smart™, planned commercialization in 2026, and ongoing research on PBIO programs and genomics subscriptions.
ProPhase Labs, Inc. reported fiscal 2025 results with revenue of $4.35M, down from $6.77M a year earlier, while gross profit improved to $1.38M and diluted EPS was ($1.74).
Financial Highlights
| Metric | Current year | Prior year | YoY change |
| Revenue¹ | $4.35M | $6.77M | (35.8%) |
| Net income² | $1.38M | ($150K) | 1022.7% |
| Diluted EPS³ | ($1.74) | ($26.68) | 93.5% |
¹ Reported as “Revenues, net”. ² Reported as “Gross profit (loss)”. ³ Reported as “loss per share, basic and diluted”.
Business Highlights
- Revenue fell 35.8% YoY to $4.3M in 2025, driven by reduced consumer product sales and the cessation of diagnostic testing operations.
- The company is pivoting from diagnostics toward genomics and direct-to-consumer whole genome sequencing offerings, including Nebula and DNA Complete, and is developing retail FDM plans.
- BE‑Smart™ achieved key validation and received a U.S. patent in 2025; management plans phased commercialization in 2026 with insurer rollout efforts.
- Diagnostic subsidiaries ceased testing, entered Chapter 11 in September 2025 and were deconsolidated, prompting a refocus of labs and reductions in G&A.
- Research and commercial efforts continue on PBIO programs (Equivir/Linebacker), TK Supplements and scaling genomics subscriptions, platform tools and lab partnerships.
Original SEC Filing: ProPhase Labs, Inc. [ PRPH ] - 10-K - Jun. 01, 2026